Xenon MRI in Pulmonary Hypertension
The overall objective outlined in this study is to determine how pulmonary vascular remodeling in PAH at a cellular and pathological level is associated with changes in gas exchange physiology and hemodynamics (monitored with 129Xe MRI/MRS) and how these signals change with disease progression or treatment.
⁃ Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the trial:
• Outpatients of either gender, Age 18-75
• Awaiting a lung transplant
• Diagnosis of precapillary PH (right heart catheterization demonstrating hemodynamic criteria of a mean pulmonary artery pressure (mPAP) ≥ 25 mmHg, pulmonary vascular resistance ≥ 3 WU, pulmonary capillary wedge pressure ≤ 15 mmHg) in the setting of Group 1 (PAH), 3 (PH due to chronic lung disease, 4 (PH due to pulmonary artery obstructions), or 5 (PH due to miscellaneous causes)
• Willing and giving informed consent and adhere to visit/protocol schedules (consent must be given before any study procedures are performed).
• Women of childbearing potential must have a negative urine pregnancy test before MRI
⁃ Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the trial:
• Treatment naïve or treatment started within the last 3 months
• Outpatients of either gender, Age 18-75
• WHO functional class (FC) 2-3 symptoms with a diagnosis of group 1 PH (mean pulmonary artery pressures (mPAP) \> 20 mmHg, pulmonary capillary wedge pressure (PCWP) ≤ 15mmHg and pulmonary vascular resistance (PVR) ≥3 WU)
• Willing and able to give informed consent and adhere to visit/protocol schedules (consent must be given before any study procedures are performed).
• Women of childbearing potential must have a negative urine pregnancy test before MRI